Indications broaden
Executive Summary
Lipitor receives approval Dec. 2 for new indication of increasing HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb)